Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations

Giuseppe Lippi, Khosrow Adeli, Khosrow Adeli, Maurizio Ferrari, Andrea R. Horvath, David Koch, Sunil Sethi, Cheng Bin Wang

Research output: Contribution to journalReview articlepeer-review


Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories.

Original languageEnglish
Pages (from-to)1053-1062
Number of pages10
JournalClinical Chemistry and Laboratory Medicine
Issue number7
Publication statusPublished - Jul 1 2020


  • biosafety
  • coronavirus disease 2019
  • COVID-19
  • laboratory
  • SARS-COV-2

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations'. Together they form a unique fingerprint.

Cite this